Lumos Diagnostics (ASX:LDX) partnered with MedPro Associates to provide national contract sales coverage for its point-of-care test, FebriDx, across hospital and primary care markets in the US, according to a Monday filing with the Australian bourse.
MedPro will provide over 60 territory representatives to increase awareness and adoption of the FebriDx technology designed to differentiate between bacterial and non-bacterial infections, the filing said.
Financial terms of the collaboration were not disclosed.